• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Painful Diabetic Neuropathy Treatment: A Guideline Topline

Slideshow

Painful diabetic neuropathy (PDN) affects more than 16% of patients with diabetes and is the most common form of peripheral neuropathy.

The American Academy of Neurology recently issued a guideline on oral and topical treatments for PDN published in the journal Neurology, which updated its 2011 guidance. Authors searched the literature from January 2008 to April 2020 using a structured review process to classify the evidence and develop practice recommendations. In the slides below, find a concise summary of the guideline.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024 / Image credit: ©Rasi/AdobeStock

New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024

Sydney Jennings
October 23rd 2024
Article

In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of baseline kidney function and glycemic control.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial / image credit heart and kidneys: ©krishnacreations/stock.adobe.com

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial

Grace Halsey
October 21st 2024
Article

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Obesity & Pain Management: A Primary Viewpoints Podcast

Obesity & Pain Management: A Primary Viewpoints Podcast

Sydney Jennings
April 27th 2023
Podcast

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

Depression, Anxiety in Youth with Chronic Pain: Daily Dose / image credit: ©New Africa/AdobeStock

Depression, Anxiety in Youth with Chronic Pain: Daily Dose

Sydney Jennings
October 15th 2024
Article

Your daily dose of the clinical news you may have missed.

FDA Faces Law Suit Over Sudden Removal of Tirzepatide from Drug Shortage List / image credit Mounjaro: ©MK Photo/stock.adobe.com

FDA Faces Law Suit Over Sudden Removal of Tirzepatide from Drug Shortage List

Ashley Gallagher;Grace Halsey
October 15th 2024
Article

Update: The FDA has told compounding pharmacies they may resume production of tirzepatide products while the agency further investigates supply.

© 2024 MJH Life Sciences

All rights reserved.